Activation of the JAK/STAT1 pathway can upregulate the expression of pro‐inflammatory factor interleukin (IL)‐1 and pro‐fibrotic factor tumor growth factor (TGF)‐β in the kidney; thus, STAT1 may be a potential therapeutic target for CKD [14]. Here, STAT1 is linked to chronic kidney disease.